Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a clinical-stage biopharmaceutical leader pioneering neuroscience therapies for central nervous system disorders. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory developments, strategic partnerships, and quarterly results. Our aggregation ensures timely access to material information about CERE's neuropharmacology pipeline targeting Parkinson's, Alzheimer's, and schizophrenia.
All content is verified at source to maintain compliance with financial disclosure standards. Bookmark this page for streamlined tracking of Cerevel's advancements in receptor-specific therapies and neuroscience innovation.
Cerevel Therapeutics (Nasdaq: CERE) announced that its chairperson and CEO, Tony Coles, M.D., will present at the 2023 BofA Securities Health Care Conference on May 10th at 10:00 am PT (1:00 pm ET). The presentation will be accessible via a live webcast on the investor relations section of the Cerevel website, with a replay available afterwards.
Cerevel focuses on treating neuroscience diseases by leveraging expertise in neurocircuitry and receptor subtype selectivity. The company has a diversified pipeline that includes five clinical-stage investigational therapies and preclinical compounds aimed at conditions such as schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder, and Parkinson's disease.
Cerevel Therapeutics (Nasdaq: CERE) has announced it will report its first quarter 2023 financial results and business updates on May 3, 2023, before the U.S. markets open. A conference call to discuss these results is scheduled for the same day at 8:00 a.m. ET, which will be accessible via registration. Cerevel is focused on treating neuroscience diseases and has a diversified pipeline with five clinical-stage investigational therapies aimed at conditions such as schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, and Parkinson’s disease. The company emphasizes its commitment to advancing research and development while exploring new avenues through collaborations or acquisitions. More details are available on their investor website.
Cerevel Therapeutics (Nasdaq: CERE) announced that its chairperson and CEO Tony Coles will participate in a fireside chat during the Stifel Virtual 2023 CNS Days on March 29, 2023, at 10:30 am ET. The event will highlight the company's ongoing commitment to neuroscience diseases and its diversified pipeline, which includes five clinical-stage investigational therapies aimed at conditions like schizophrenia, Alzheimer’s disease psychosis, and epilepsy. A live webcast of the presentation will be available on the investor relations section of Cerevel's website, with a replay accessible afterward.
Cerevel Therapeutics (Nasdaq: CERE) announced that its chairperson and CEO, Tony Coles, M.D., will present at the 43rd Annual Cowen Health Care Conference. The presentation is scheduled for March 6, 2023, at 9:10 a.m. EST, and can be accessed via a live webcast on Cerevel's investor relations website. Cerevel is focused on neuroscience diseases, offering a diversified pipeline that includes five clinical-stage therapies targeting conditions like schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder, and Parkinson's disease. A replay of the presentation will also be available on their website.
